摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

((cyclohexyloxy)carbonyl)-1-leucine | 3309-47-5

中文名称
——
中文别名
——
英文名称
((cyclohexyloxy)carbonyl)-1-leucine
英文别名
(2S)-2-(cyclohexyloxycarbonylamino)-4-methylpentanoic acid
((cyclohexyloxy)carbonyl)-1-leucine化学式
CAS
3309-47-5
化学式
C13H23NO4
mdl
——
分子量
257.33
InChiKey
SRBFBUWTOMWUGE-NSHDSACASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    18
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.85
  • 拓扑面积:
    75.6
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    ((cyclohexyloxy)carbonyl)-1-leucine甲醇锂硼氢戴斯-马丁氧化剂N,N-二异丙基乙胺 作用下, 以 四氢呋喃二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 28.5h, 生成 cyclohexyl ((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)carbamate
    参考文献:
    名称:
    [EN] BROAD SPECTRUM ANTIVIRALS AGAINST CORONAVIRUS
    [FR] ANTIVIRAUX À LARGE SPECTRE CONTRE LE CORONAVIRUS
    摘要:
    显示抗病毒活性和/或针对病毒复制的抑制作用的化合物,特别是属于类似小核糖病毒超簇的病毒,包括具有以下结构的冠状病毒:(I),其中X包括一个环状基团,R2是支链或非支链烷基,环烷基,芳基,芳基烷基,烯基,炔基,氨基酸侧链,双环或三环侧链,它们的组合和取代形式,Z选自羟基烷基,醛,α-酮胺和亚硫酸盐等物种组成的群体,特别是-CH2OH,-CHO,-CH(0H)S03-Na+,以及-[0(C=0)Rw]S03-Na+。
    公开号:
    WO2021202460A1
  • 作为产物:
    描述:
    (S)-(-)-2-异氰酰基-4-甲基戊酸甲酯三乙胺 、 lithium hydroxide 作用下, 以 四氢呋喃乙腈 为溶剂, 反应 5.0h, 生成 ((cyclohexyloxy)carbonyl)-1-leucine
    参考文献:
    名称:
    [EN] BROAD SPECTRUM ANTIVIRALS AGAINST CORONAVIRUS
    [FR] ANTIVIRAUX À LARGE SPECTRE CONTRE LE CORONAVIRUS
    摘要:
    显示抗病毒活性和/或针对病毒复制的抑制作用的化合物,特别是属于类似小核糖病毒超簇的病毒,包括具有以下结构的冠状病毒:(I),其中X包括一个环状基团,R2是支链或非支链烷基,环烷基,芳基,芳基烷基,烯基,炔基,氨基酸侧链,双环或三环侧链,它们的组合和取代形式,Z选自羟基烷基,醛,α-酮胺和亚硫酸盐等物种组成的群体,特别是-CH2OH,-CHO,-CH(0H)S03-Na+,以及-[0(C=0)Rw]S03-Na+。
    公开号:
    WO2021202460A1
点击查看最新优质反应信息

文献信息

  • Cyclohexyloxycarbonyl based orthogonal solid phase peptide synthesis in Boc chemistry
    作者:Gábor Mezö、Nikolett Mihala、György Kóczán、Ferenc Hudecz
    DOI:10.1016/s0040-4020(98)00360-3
    日期:1998.6
    Application of N-cyclohexyloxycarbonyl (Choc) protection in Boc chemistry on solid phase provides a new possibility for the preparation of protected peptide fragments. A Choc/OcHex protection scheme allows also the assembly of cyclic lactam peptides linked to the resin through the C-terminus. Choc protection is stable under the 1M TMSOTf-thioanisole/TFA cleavage condition at 0 degrees C, but it is removable by anhydrous HF. We have utilized cyclohexyloxycarbonyl as an orthogonal protecting group for the synthesis of a i) bicyclic epitope peptide of glycoprotein D of HSV 1 on BHA resin and ii) fully protected hexapeptide involved in protein transport on Merrifield resin. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
  • Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 2. Peptide Structure−Activity Studies
    作者:Peter S. Dragovich、Stephen E. Webber、Robert E. Babine、Shella A. Fuhrman、Amy K. Patick、David A. Matthews、Siegfried H. Reich、Joseph T. Marakovits、Thomas J. Prins、Ru Zhou、Jayashree Tikhe、Ethel S. Littlefield、Ted M. Bleckman、Michael B. Wallace、Thomas L. Little、Clifford E. Ford、James W. Meador、Rose Ann Ferre、Edward L. Brown、Susan L. Binford、Dorothy M. DeLisle、Stephen T. Worland
    DOI:10.1021/jm9800696
    日期:1998.7.1
    The structure-based design, chemical synthesis, and biological evaluation of various peptide-derived human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of an ethyl propenoate Michael acceptor moiety and a tripeptidyl binding determinant. The systematic modification of each amino acid residue present in the binding determinant as well as the N-terminal functionality is described. Such modifications are shown to provide irreversible HRV-14 3CP inhibitors with anti-3CP activities (k(obs)/[I]) ranging from 60 to 280 000 M-1 s(-1) and antiviral EC50's which approach 0.15 mu M. An optimized inhibitor which incorporates several improvements identified by the structure-activity studies is also described. This molecule displays very rapid irreversible inhibition of HRV-14 3CP (k(obs)/[I] = 800 000 M-1 s(-1)) and potent antiviral activity against HRV-14 in cell culture (EC50 = 0.056 mu M). A 1.9 Angstrom crystal structure of an S-alkylthiocarbamate-containing inhibitor complexed with HRV-8 3CP is also detailed.
  • Azole Endothelin Antagonists. 3. Using Δ log <i>P</i> as a Tool To Improve Absorption
    作者:Thomas W. von Geldern、Daniel J. Hoffman、Jeffrey A. Kester、Hugh N. Nellans、Brian D. Dayton、Samuel V. Calzadilla、Kennan C. Marsh、Lisa Hernandez、William Chiou、Douglas B. Dixon、Jinshyun R. Wu-Wong、Terry J. Opgenorth
    DOI:10.1021/jm9505932
    日期:1996.1.1
    The oral absorption profile of a family of azole-based ET(A)-selective antagonists has been improved through a rational series of structural modifications which were suggested by analysis of the physicochemical parameter Delta log P. Comparison of urea 2 with a series of well-absorbed compounds using Delta log P analysis suggested that 2 has an excess capacity for forming hydrogen bonds with solvent. A series of urea modifications were explored as a means of reducing H-bonding capacity while maintaining affinity for the ET(A)-receptor. The correlation between Delta log P values and absorption in an intraduodenal (id) bioavailability model was good; this strategy uncovered replacements for each of the urea NH groups which simultaneously improve both potency and drug absorption. A combination of these optimized modifications produces carbamate 16h, a highly-selective ET(A) antagonist with a potency/bioavailability profile consistent with an oral route of administration.
  • [EN] BROAD SPECTRUM ANTIVIRALS AGAINST CORONAVIRUS<br/>[FR] ANTIVIRAUX À LARGE SPECTRE CONTRE LE CORONAVIRUS
    申请人:UNIV KANSAS STATE
    公开号:WO2021202460A1
    公开(公告)日:2021-10-07
    Compounds exhibiting antiviral activity and/or inhibition of viral replication against viruses, particularly those belonging to the picornavirus-like supercluster, including coronavirus having a formula: (I) where X comprises a cyclic moiety, R2 is a branched or unbranched alkyl, cycloalkyl, aryl, arylalkyl, alkenyl, alkynyl, amino acid side chain, bicyclic or tricyclic side chain, combinations, and substituted forms thereof, and Z is selected from the group consisting of C1-C6 hydroxyalkyl, aldehydes, alpha- ketoamides, and bisulfite salts, and in particular -CH2OH, -CHO, -CH(0H)S03 -Na+, and - [0(C=0)Rw]S03 -Na+.
    显示抗病毒活性和/或针对病毒复制的抑制作用的化合物,特别是属于类似小核糖病毒超簇的病毒,包括具有以下结构的冠状病毒:(I),其中X包括一个环状基团,R2是支链或非支链烷基,环烷基,芳基,芳基烷基,烯基,炔基,氨基酸侧链,双环或三环侧链,它们的组合和取代形式,Z选自羟基烷基,醛,α-酮胺和亚硫酸盐等物种组成的群体,特别是-CH2OH,-CHO,-CH(0H)S03-Na+,以及-[0(C=0)Rw]S03-Na+。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物